1. Polydopamine Nanoparticles Camouflaged by Stem Cell Membranes for Synergistic Chemo-Photothermal Therapy of Malignant Bone Tumors
- Author
-
Lian Duan, Pu Shao, Meng Meng Zhang, Fuqiang Zhang, Xupeng Mu, Jinlan Jiang, Te Liu, and Jun Yan
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Biocompatibility ,education ,Biophysics ,Pharmaceutical Science ,Bioengineering ,02 engineering and technology ,010402 general chemistry ,01 natural sciences ,Flow cytometry ,Biomaterials ,In vivo ,health services administration ,Drug Discovery ,medicine ,medicine.diagnostic_test ,Chemistry ,fungi ,Organic Chemistry ,Mesenchymal stem cell ,Photothermal effect ,technology, industry, and agriculture ,General Medicine ,Photothermal therapy ,021001 nanoscience & nanotechnology ,In vitro ,0104 chemical sciences ,Cancer research ,Stem cell ,0210 nano-technology - Abstract
Purpose Nanoparticle (NP)-based chemo-photothermal therapy (CPT) has been shown to be a promising non-invasive approach for antitumor treatment. However, NPs must overcome the limitations of opsonization, clearance of the reticuloendothelial system, and ineffective targeting of tumor tissue sites. To solve these problems, stem cell membrane (SCM)-camouflaged polydopamine nanoparticles (PDA@SCM NPs) carrying the hydrophobic anticancer drug 7-ethyl-10-hydroxycamptothecin (SN38) were constructed for CPT of malignant bone tumors. Methods We developed umbilical-cord mesenchymal stem cell membrane-coated polydopamine nanoparticles encapsulating SN38 (PDA-SN38@SCM NPs) as an efficient tumor-targeting drug-delivery platform for CPT of malignant bone tumors. We characterized PDA@SCM NPs and evaluated the biocompatibility and anti-phagocytosis properties of PDA@SCM NPs. The antitumor activity of PDA-SN38@SCM NPs was evaluated in MG63 lines and an MG63 xenograft model in mice. Results Synthesized PDA-SN38@SCM NPs retained an excellent photothermal effect after SN38 loading. The drug release of PDA-SN38@SCM NPs could be triggered by near-infrared irradiation and an acidic stimulus. PDA@SCM NPs exhibited lower nonspecific macrophage uptake, longer retention in blood, and more effective accumulation at tumor sites than that shown by PDA NPs. Confocal laser scanning microscopy (CLSM) and flow cytometry showed that MG63 cells took up more PDA-SN38@SCM NPs than PDA-SN38 NPs. In vitro and in vivo antitumor studies demonstrated the outstanding performance of PDA-SN38@SCM NPs in synergistic CPT for bone tumors. Conclusion PDA-SN38@SCM NPs demonstrated an extraordinary synergistic CPT effect and could be a promising strategy for the treatment of malignant bone tumors.
- Published
- 2020